Valeant Pharmaceuticals has announced that its internal Ad-Hoc committee of board of directors — put together to dig through the troubled company’s accounting — has completed its work.
The ad-hoc committee says that it found no more issues with the company’s accounting beyond the $58 million misstatement that has forced it to delay its annual report.
The stock is up 17% in Tuesday’s pre-market trading session.
Business Insider Emails & Alerts
Site highlights each day to your inbox.